Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Jun 5, 2026

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

Validation of tissue microarray technology in malignant pleural mesothelioma.

Steven C H Kao¹, Kenneth Lee, Nicola J Armstrong

¹Asbestos Diseases Research Institute, Bernie Banton Centre, Concord, Australia.

|January 15, 2011

Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Exploring the barriers to optimal survivorship care for people living with Cancer in NSW.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026

Same author

YBX1 Expression Marks Proliferative Tumour States with Context-Dependent Genomic Instability: A Pan-Cancer Analysis.

International journal of molecular sciences·2026

Same author

MicroRNA Mimics Based on the miR-15/107 Consensus Sequence Sensitise NSCLC Cells to Targeted Therapy.

International journal of molecular sciences·2026

Same author

PAX gene expression in autosomal dominant polycystic kidney disease contributes to cyst expansion and regulates a gene network associated with cyst growth.

Human molecular genetics·2026

Same author

Inhibition of YB-1 phosphorylation enhances cisplatin activity and disrupts cell division in pleural mesothelioma.

British journal of cancer·2025

Same author

Moving from theory to practice: implementing a prehabilitation program before gastrointestinal cancer surgery (PREHAB-GI).

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2025

Tissue microarray (TMA) technology is valid for assessing malignant pleural mesothelioma (MPM) if at least four cores are used. This method accurately represents MPMs, aiding in diagnosis and research.

Area of Science:

Oncology
Pathology
Biotechnology

Background:

Malignant pleural mesothelioma (MPM) is a complex cancer with significant intralesional heterogeneity.
Tissue microarray (TMA) technology is increasingly used for cancer assessment, but its suitability for heterogeneous tumors like MPM is debated.

Purpose of the Study:

To investigate the validity of using TMAs for the accurate assessment of MPM.
To determine the minimum number of cores required for TMAs to reliably represent MPM.

Main Methods:

TMAs were constructed from 80 archival MPM tumors using at least five cores per tumor.
Immunohistochemical staining for calretinin and D2-40 was performed on TMAs and whole tissue sections.
Quantitative analysis and statistical comparison (ANOVA) were used to evaluate concordance between TMA and whole-section results.

More Related Videos

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

Related Experiment Videos

Last Updated: Jun 5, 2026

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

Main Results:

A minimum of four cores per TMA was sufficient to achieve high concordance (98-99%) with whole-section results for calretinin and D2-40.
Quantitative immunohistochemical scoring showed statistically significant correlations between TMA cores and whole sections.
Tumor block origin and age did not impact the reliability of TMA results.

Conclusions:

TMA technology is an appropriate and valid method for immunohistochemical analysis in MPM.
Using a minimum of four cores per TMA ensures reliable and representative assessment of MPM heterogeneity.